<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03913260</url>
  </required_header>
  <id_info>
    <org_study_id>17212</org_study_id>
    <secondary_id>I9N-MC-FCAC</secondary_id>
    <nct_id>NCT03913260</nct_id>
  </id_info>
  <brief_title>A Study of Different Injectable Formulations of LY3375880 in Healthy Participants</brief_title>
  <official_title>A Safety, Tolerability, and Pharmacokinetic Study of Different Solution Formulations of LY3375880 Using Investigational Injection Devices in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purposes of this study are: 1. To learn more about the safety and side effects of
      different formulations of LY3375880 and 2. To measure how much LY3375880 gets into the blood
      stream and how long it takes to get out of the body. The study will last about 85 days.
      Screening may occur up to 28 days prior to enrollment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Actual">September 19, 2019</completion_date>
  <primary_completion_date type="Actual">September 19, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Part A is a crossover design. Part B is a parallel design.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Scale (VAS) Pain Score</measure>
    <time_frame>Part A: Within 1-minute post injection</time_frame>
    <description>The pain VAS is a participant administered single item scale designed to measure pain using a 0-100 millimeter (mm) horizontal VAS. Overall severity of participant's pain is indicated by placing a single mark on the scale from 0 mm (no pain) to 100 mm (severe pain).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3375880</measure>
    <time_frame>Part B: Predose through Day 85</time_frame>
    <description>PK: Cmax of LY3375880</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve (AUC) of LY3375880</measure>
    <time_frame>Part B: Predose through Day 85</time_frame>
    <description>PK: AUC of LY3375880</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part A: LY3375880 Formulation A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3375880 Formulation A administered subcutaneously (SC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: LY3375880 Formulation B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3375880 Formulation B administered subcutaneously SC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: LY3375880 Formulation C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3375880 Formulation C administered SC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Positive Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Positive Control (buffer matrix, only) administered SC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: LY3375880 Test 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3375880 Test 1 Formulation administered SC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: LY3375880 Test 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3375880 Test 2 Formulation administered SC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: LY3375880 Test 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3375880 Test 3 Formulation administered SC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3375880</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Part A: LY3375880 Formulation A</arm_group_label>
    <arm_group_label>Part A: LY3375880 Formulation B</arm_group_label>
    <arm_group_label>Part A: LY3375880 Formulation C</arm_group_label>
    <arm_group_label>Part B: LY3375880 Test 1</arm_group_label>
    <arm_group_label>Part B: LY3375880 Test 2</arm_group_label>
    <arm_group_label>Part B: LY3375880 Test 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buffer Matrix (No LY3375880)</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Part A: Positive Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Autoinjector (AI)</intervention_name>
    <description>AI used to administer LY3375880 or Buffer Matrix</description>
    <arm_group_label>Part A: LY3375880 Formulation A</arm_group_label>
    <arm_group_label>Part A: LY3375880 Formulation B</arm_group_label>
    <arm_group_label>Part A: LY3375880 Formulation C</arm_group_label>
    <arm_group_label>Part A: Positive Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Manual Syringe</intervention_name>
    <description>Manual syringe used to inject LY3375880</description>
    <arm_group_label>Part B: LY3375880 Test 1</arm_group_label>
    <arm_group_label>Part B: LY3375880 Test 2</arm_group_label>
    <arm_group_label>Part B: LY3375880 Test 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are overtly healthy males or females, as determined by medical history and physical
             examination

          -  Have a body mass index of 18.0 to 32.0 kilograms per meter squared (kg/mÂ²) inclusive

          -  Females who are not of child-bearing potential

          -  Males who agree to use a reliable method of birth control during the study and for 120
             days following the final administration of LY3375880

          -  Are reliable and willing to make themselves available for the duration of the study
             and are willing to follow study procedures

        Exclusion Criteria:

          -  Have known allergies to LY3375880, related compounds or any components of the
             formulation, or history of significant atopy

          -  Have participated or are currently enrolled in clinical trials with LY3375880

          -  Have infections or evidence of infections

          -  Are pregnant, lactating or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Inc</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 11, 2019</study_first_submitted>
  <study_first_submitted_qc>April 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2019</study_first_posted>
  <last_update_submitted>October 9, 2019</last_update_submitted>
  <last_update_submitted_qc>October 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

